Amirhossein Fayyazi

Amirhossein Fayyazi

Auto-generated profile, based on publicly available information

Amirhossein Fayyazi

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HRHakime Rajabi
Hakime Rajabi
HSHimen Salimizand
Himen Salimizand
MKMazaher Khodabandehloo
Mazaher Khodabandehloo
AFAmirhossein Fayyazi
Amirhossein Fayyazi
RRRashid Ramazanzadeh
Rashid Ramazanzadeh
Introduction. Biofilm formation is one of the main virulence factors in Pseudomonas aeruginosa infections. This study is aimed at investigating the presence of genes involved in biofilm formation in clinical P. aeruginosa isolates. Material and Methods. A cross‐sectional study was conducted on 112 P. aeruginosa isolates. The biofilm formation assay was performed on all isolates. Antimicrobial resistance was determined by the disk diffusion method, and the presence of genes was detected by polymerase chain reaction. Isolates were typed with Rep‐PCR. Results. The results of biofilm formation demonstrated that 85 strains (75.9%) were biofilm producers, and 27 strains (24.1%) were nonproducer isolates. Antibiotic susceptibility pattern in biofilm‐positive and biofilm‐negative isolates obtained from hospitalized patients showed a high rate of antibiotic resistance to amoxicillin with 95.7% and 92.3%, respectively. Based on PCR amplification results, the frequency of genes involved in biofilm formation among all isolates was as follows: algD (78.6%), pelF (70.5%), pslD (36.6%), Ppgl (0%), and PAPI-1 (77.6%). Rep‐PCR typing demonstrated that 112 P. aeruginosa isolates were classified into 57 types according to 70% cut‐off. The predominant type was A which contained 15 isolates. Moreover, 7 isolates were clustered in genotype B, followed by C type (6), D (4), E (4), F (4), G (4), H (3), I (3), J (3 isolates), and 12 genotypes, each containing two isolates. Also, 35 isolates were distributed in scattered patterns and showed single types. Conclusion. Study results showed significant association between biofilm formation and resistance to antibiotics such as ceftazidime and meropenem. Analysis of Rep‐PCR patterns indicated that the evaluated isolates were heterogeneous, relatively.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ASAmin Sadeghi
Amin Sadeghi
MHMehrdad Halaji
Mehrdad Halaji
AFAmirhossein Fayyazi
Amirhossein Fayyazi
SHSeyed Havaei
Seyed Havaei
Introduction. Urinary tract infection (UTI) is one of the most frequent infections in kidney transplant patients (KTPs). This infection is mainly caused by uropathogenic Escherichia coli (UPEC). Plasmid‐mediated quinolone resistance (PMQR) was also increasingly identified in UPEC. This study proposed to investigate the frequency of quinolone‐resistance plasmid genes and the O‐antigen serogroup among UPEC isolated from KTPs and non‐KTP with UTI. Methods. Totally, 114 UPEC isolates from 49 KTPs and 65 non‐KTPs patients diagnosed with an UPEC‐associated UTI were obtained from June 2019 to December 2019 at three laboratory centers in Isfahan, Iran. The isolates were confirmed through phenotypic and genotypic methods. Moreover, the antimicrobial susceptibility test to nalidixic acid, ciprofloxacin, norfloxacin, and ofloxacin was performed using a disk diffusion method. The presence of the qnr gene as well as the serogroup distribution was identified using the PCR method. Result. According to data, the distribution of O1, O2, O4, O16, and O25 serogroups were 3.5%, 2.6, 3.5, 3.5, and 20.2%, respectively. Antibiotic susceptibility pattern revealed that the highest and lowest resistance rates were to nalidixic acid (69.3%) and norfloxacin (43.9%), respectively. Also, the frequency of qnrS and qnrB genes were 33.3% and 15.8%, respectively, while none of the isolates was found to be positive for the qnrA gene. There was no significant association between the presence of qnr genes and higher antibiotic resistance. Conclusion. This study recognized that the qnrS gene, O25 serotype, and resistance to nalidixic acid had the highest frequencies in UPEC strains isolated from UTI patients.

5 November 2025 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
AFAmirhossein Fayyazi
Amirhossein Fayyazi
MKMansoor Kodori
Mansoor Kodori
MHMinoo Hosseinpour
Minoo Hosseinpour
AHAli Hashemi
Ali Hashemi
FRFariba Rafiei
Fariba Rafiei

1 January 2026 in International Journal of Microbiology
Verified
Journal Article
Open access
MJMohsen Javidi
Mohsen Javidi
ZGZohreh Ghalavand
Zohreh Ghalavand
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
AFAmirhossein Fayyazi
Amirhossein Fayyazi
MTMaryam Tarhani
Maryam Tarhani
AHAli Hashemi
Ali Hashemi
Background: Escherichia coli and Klebsiella pneumoniae are recognized as significant opportunistic pathogens responsible for a substantial proportion of hospital‐acquired infections. The growing prevalence of multidrug resistance in isolates of these pathogens represents a critical global health concern. Tigecycline, a broad‐spectrum antibiotic, has demonstrated efficacy in the treatment of carbapenem‐resistant Enterobacteriaceae. The present study is aimed at investigating the mechanisms underlying tigecycline resistance in clinical isolates of E. coli and K. pneumoniae. Methods: This study included 103 clinical isolates of E. coli and K. pneumoniae obtained from hospitalized patients in selected Tehran hospitals during 2022–2023. Isolates were identified and confirmed through standard microbiological phenotypic techniques. Antimicrobial susceptibility testing was conducted using the disk diffusion method and minimum inhibitory concentration (MIC) determination following Clinical and Laboratory Standards Institute (CLSI) guidelines. Polymerase chain reaction (PCR) and sequencing were employed to detect resistance genes ( acrR, acrB, oqxA, oqxB, marA, tet(X), and ramA ) and identify mutations. Gene expression analysis for acrB, ramA, and marA was performed using real‐time PCR. Tigecycline‐resistant isolates were subjected to MLST for molecular typing. Results: Among the 103 isolates, 58 were identified as E. coli and 45 as K. pneumoniae . The lowest resistance rates were observed for doripenem (18.4%, 19/103) and tigecycline (0.97%, 1/103). Notably, an additional 15 isolates (14.6%) exhibited intermediate susceptibility to tigecycline. Among the 16 tigecycline nonsusceptible isolates (1 resistant and 15 intermediate; 4 E. coli and 12 K. pneumoniae ), all harbored the acrR , acrB , oqxA , and marA genes, whereas 93.7% (15/16) carried the ramA and oqxB genes. None of the isolates contained the tet(X) gene. The MIC range for these isolates was 0.5–8 μ g/mL. One tigecycline‐resistant K. pneumoniae isolate (K9) exhibited a mutation in the acrB gene. Expression analysis revealed significant upregulation of marA , followed by acrB and ramA . MLST analysis identified isolate K9 as belonging to sequence type ST268. Conclusion: In this study, it was found that resistance to tigecycline was low (0.97%), but 14.6% of the samples were intermediate, indicating an increase in resistance to this antibiotic. Tigecycline can still be considered a suitable option for carbapenem‐resistant isolates, but its administration requires careful consideration.

13 December 2025 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
HGHossein Goudarzi
Hossein Goudarzi
ZGZohreh Ghalavand
Zohreh Ghalavand
MGMehdi Goudarzi
Mehdi Goudarzi
MJMohsen Javidi
Mohsen Javidi
AHAli Hashemi
Ali Hashemi
An alert has been issued regarding the widespread emergence of multidrug-resistant (MDR) and carbapenem-resistant Klebsiella pneumoniae (CRKP) in hospital

1 January 2026 in International Journal of Microbiology
Verified
Journal Article
Open access
PDF file
MGMohammad Javad Roustaye Gourabi
Mohammad Javad Roustaye Gourabi
ANAnita Nikoo
Anita Nikoo
BKBita Khanbabaei
Bita Khanbabaei
MKMasoud Kargar
Masoud Kargar
AFAmirhossein Fayyazi
Amirhossein Fayyazi
JSJavad yasbolaghi Sharahi
Javad yasbolaghi Sharahi
β ‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β ‐lactamase enzymes. The proliferation of these enzymes represents a critical threat to global public health, compounding therapeutic challenges and escalating healthcare costs. As the efficacy of conventional treatments diminishes, reliance on last‐resort agents like carbapenems and colistin has increased, in turn accelerating resistance to these precious final‐line options. To address this escalating crisis, the strategic combination of β ‐lactam antibiotics with β ‐lactamase inhibitors (BLIs) has emerged as a vital therapeutic approach, restoring the activity of β ‐lactams by inactivating the resistance enzymes. Since the introduction of clavulanic acid, significant progress has been made in expanding the BLI arsenal. This review provides a comprehensive analysis of the current landscape of novel BLIs that have been approved or are in advanced clinical development, delving into their distinct mechanisms of action, spectra of activity against Ambler molecular classes (A, B, C, and D), and evolving clinical applications. While early inhibitors primarily targeted serine‐ β ‐lactamases (SBLs), recent advancements have introduced agents with expanded profiles, including those effective against some Class D carbapenemases. A paramount, ongoing challenge remains the development of effective inhibitors against metallo‐ β ‐lactamases (MBLs), though promising candidates like taniborbactam and xeruborbactam are now in clinical development. This review synthesizes the current knowledge on these innovative inhibitors, from recently approved combinations like ceftazidime/avibactam and cefepime/enmetazobactam to those in advanced clinical trials, and critically examines the associated therapeutic challenges, including the emergence of resistance. By integrating mechanistic insights with clinical perspectives, this article is aimed at informing the ongoing battle against antimicrobial resistance and guiding the future development of life‐saving therapeutic strategies.